Introduction
It has been shown repeatedly that among patients with acute lymphoblastic leukaemia adults have a worse prognosis than children.' This finding has been confirmed at St Bartholomew's Hospital, where in 1970-2 complete remission was achieved in only 15 out of 32 adults (470,) on vincristine and prednisolone alone (unpublished data). This combination induces remission in most children, although it became evident in the late 1960s that high-risk groups existed in which the remission rate was lower and overall survival shorter. The identification of those high-risk groups was followed by the study of more intensive chemotherapy programmes. Bernard et a12 and Mathe et al3 added an anthracycline to vincristine and prednisolon-e and achieved 100"!o complete remission in small series of such highrisk patients. Aur et all added colaspase (L-asparaginase) to the above combination and obtained identical results without excess toxicity. This four-drug combination was also effective in patients who had relapsed on other treatment. 5 These results prompted us to try to improve the results of treatment for adults by intensifying the initial chemotherapy and introducing early "prophylaxis" of the central nervous system (CNS). We report here the results in the first 51 patients entered into the study.
Patients and methods
The 51 consecutive untreated patients who entered the study from December 1972 to Mlay 1976 were all aged over 15 and had acute lymphoblastic leukaemia (see table II ). All patients were evaluable and none had to be excluded.
All patients satisfied the minimum diagnostic criteria of bone marrow infiltration with at least 30'. blast cells with a high nuclear: cytoplasmic ratio and one or two nucleoli. Five patients whose leukaemic cells were morphologically identical to those found in Burkitt's lymphoma,j as described by Flandrin et al,7 were included in the series. The blast cells were negative to the Sudan black stain, and cytogenetic analysis showed that all 51 patients were negative for the Philadelphia chromosome.
DEFINITIONS
Cottmplete remnissionz was considered to have occurred when there were no clinical manifestations of leukaemia; the peripheral blood count was normal; the bone marrow contained less than 5 so blasts, none of which were obviously leukaemic; and a cytocentrifuge preparation of the cerebrospinal fluid (CSF) contained no blast cells. Patients with blast cells in the CSF at clinical and haematological remission were deemed to be in complete remission when there had been two consecutive blast-free specimens of CSF during CNS treatment.
Relapse-When blast cells reappeared in the peripheral blood, bone marrow, or CSF the patient was considered to have relapsed. After January 1975 the bone marrow and CSF were studied routinely every two months. Before then they were examined only when there were clinical or haematological indications.
Remnission duirationi was taken as the length of time from the date of complete remission to relapse.
Suri-vival was the length of time from the date of diagnosis to death.
TREATMENT PROGRAMME
The treatment programme included three main elements: the induction and consolidation of remission (table I) , treatment of the CNS or CNS prophylaxis, and maintenance treatment. 
Results

REMISSION
Thirty-six patients (71 ",,) achieved complete remission on doxorubicin, vincristine, prednisolone, and colaspase (table II) . This remission rate was significantly better (P < 005) than that in our previous study using only vincristine and prednisolone, in which only 15 (47 ,) out of 32 patients achieved complete remission.
Twenty-four patients achieved haematological remission after four courses of doxorubicin and vincristine and the remaining 12 after a further two courses (and in four cases a small amount of oral chemotherapy). At the time of haematological remission four of the 36 patients had clinical evidence of disease. Two of these patients had splenomegaly, which was treated by splenectomy, and one had lymphadenopathy and underwent lymph node biopsy; neither the spleens nor the lymph nodes were found to contain leukaemic cells. The fourth patient had radiological evidence of residual tumour in the chest, which disappeared after local radiotherapy. All four patients achieved complete remission after this further treatment.
Examination of the cytocentrifuge specimen of the CSF at this stage showed unequivocal blasts in six of the 36 asymptomatic patients (table II) . Details of these patients have been reported elsewhere.h They included both patients with Burkitt-like leukaemia who achieved clinical and haematological remission. In all cases blasts were cleared from the CSF by CNS treatment-that is, treatment with five doses of intrathecal methotrexate 12 5 mg followed by five doses of intrathecal cytarabine 50 mg given over four weeks in combination with craniospinal irradiation (2400 rads) in five cases and with cranial irradiation (2400 rads) in 
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Patients who did not achieve remission <2  NR  NR  <2  <2  NR  NR  <2  <2  NR  <2  <2  NR   <2   NR   NR   ,,,   , between these patients (0 out of 4) and those with no clinical CNS disease (36 out of 47). None of the other factors investigated (age, sex, presence of hepatomegaly or splenomegaly, morphology of the blast cells, the periodic acid Schiff reactivity of the blast cells, the height of the blast cell count, or the platelet count at presentation) had a significant effect on the complete remission rate, although both increasing age and Burkitt-like morphology tended to influence the complete remission rate adversely. 
SURVIVAL
The predicted median survival of all patients was 21 months, with patients who achieved remission having a predicted median survival of 27 months and those who did not achieve remission a median survival of less than 1 month (P < 0-01) (fig 3) .
FACTORS AFFECTING LENGTH OF REMISSION
The extent of disease at presentation influenced the duration of complete remission. Clinical hepatomegaly and clinical splenomegaly both reduced the duration of complete remission significantly (P=001 and P=005 respectively; table IV), and a combination of the two reduced it very significantly (P < 0 001) (fig 2) . Patients with an initial peripheral blood blast cell count greater than 10 x 109/1 had a shorter remission than those with a blast cell count of less than 10 x 109/1 (P < 0-03) ( All patients suffered alopecia and myelosuppression. Only one had severe neurotoxicity. Nausea and vomiting were rarely problems provided appropriate antiemetics were given before chemotherapy, but four patients had to stop taking colaspase because of nausea and vomiting. About half the patients developed glycosuria while receiving prednisolone and colaspase, and about 10'. needed either insulin or an oral antidiabetic agent. Antidiabetic treatment was no longer required after colaspase was stopped. The colaspase was stopped in one patient because of a raised blood urea concentration. Hypersensitivity and pancreatitis were not observed.
Discussion
The complete remission rate in adults with acute lymphoblastic leukaemia treated at St Bartholomew's Hospital has been improved significantly by the addition of doxorubicin and colaspase to vincristine and prednisolone. The modification of the treatment programme by increasing the intervals between courses of doxorubicin and vincristine to a minimum of two weeks has improved the results further, with complete remission being achieved in all 16 of the patients who received at least two courses.
These results were found in the largest series of adults with acute lymphoblastic leukaemia treated at one centre and are supported by the results of other studies. With two exceptions," l both reporting small numbers of cases, all groups of workers have found it necessary to supplement vincristine and prednisolone with additional drugs to obtain high complete remission rates in adults with acute lymphoblastic leukaemia. In most cases1-3 " an anthracycline antibiotic has been used, although other combinations have also been shown to be effective.' 21 From our data we cannot comment on the value of colaspase, although the results of a randomised study of patients with both acute lymphoblastic and acute myeloblastic leukaemia have suggested that it does not improve the complete remission rate. 22 The length of complete remission is probably related to the intensity of initial treatment. The longest remissions have been reported by Gee et al,'5 who used very intensive early treatment. Others, using less intensive early therapy, have reported considerably shorter remissions, which did not seem to be influenced by reinduction treatment." 1314 The predicted median duration of complete remission in our series was 18 5 months, which, although slightly shorter than that of Gee et al, is better than any other. It was clearly influenced by the extent of disease at presentation, both hepatosplenomegaly and a high circulating blast count being adverse prognostic factors. Patients with these presenting features might benefit from a further intensification of treatment.
CNS prophylaxis with cranial irradiation and intrathecal methotrexate clearly improves the prognosis in childhood lymphoblastic leukaemia.
We cannot yet evaluate fully the role of early CNS treatment in our patients, since only 17 patients have relapsed so far. The incidence of CNS relapse before bone marrow relapse was disturbingly high in our series (three of the 13 patients receiving CNS prophylaxis and two of the four receiving CNS treatment). This may not be representative of the whole group, however, since 18 patients remain in remission. In children there is some suggestion that methotrexate alone, given either intrathecally or intrathecally and intravenously, may be as effective as when combined with CNS prophylaxis. A high incidence of CNS relapse in adults treated with intrathecal methotrexate alone as CNS prophylaxis has been reported,'5 but treatment was continued for only a short period. Willemze et al, 1 using intrathecal methotrexate during remission and at increasing intervals during maintenance, reported it to be as effective as the combination of intrathecal methotrexate and cranial irradiation and showed a very low incidence of relapses occurring in the CNS first. Clearly, more information is required on the comparative effectiveness of prophylactic methotrexate with or without the addition of CNS irradiation.
From our data and those of others we have therefore reached the following conclusions. Firstly, intensification of the early treatment of acute lymphoblastic leukaemia improves the complete remission rate and probably the length of remission, but the courses of treatment do not have to be given at very close intervals. Secondly, early CNS treatment is essential. Thirdly, the extent of disease at presentation influences the prognosis, and the amount of early treatment in patients with extensive disease should probably be increased. Finally, Burkitt-like leukaemia can be recognised as a separate entity associated with CNS disease and a poor prognosis and may benefit from a different therapeutic approach.
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